Delving into the Latest Updates on Anthraxumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-anthrax monoclonal antibodies, Anti-anthrax monoclonal antibodies(IQ therapeutics), IQ-DAA

+ [5]

Target

Antrax lethal toxin

Action

inhibitors

Mechanism

Antrax lethal toxin inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Anthrax

Originator Organization

IQ Therapeutics BV

Active Organization-

Inactive Organization

IQ Therapeutics BV

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Anthrax toxin is a critical virulence factor of Bacillus anthracis. The toxin comprises protective antigen (PA) and two enzymatic moieties, edema factor (EF) and lethal factor (LF), forming bipartite lethal toxin (LT) and edema toxin (ET). PA binds cellular surface receptors and is required for intracellular translocation of the enzymatic moieties. For this reason, anti-PA antibodies have been developed as therapeutics for prophylaxis and treatment of human anthrax infection. Assays described publicly for the control of anti-PA antibody potency quantify inhibition of LT-mediated cell death or the ET-induced increase in c-AMP levels. These assays do not fully reflect and/or capture the pathological functions of anthrax toxin in humans. Herein, we report the development of a cell-based gene reporter potency assay for anti-PA antibodies based on the rapid LT-induced degradation of c-Jun protein, a pathogenic effect that occurs in human cells. This new assay was developed by transducing Hepa1c1c7 cells with an AP-1 reporter lentiviral construct and has been qualified for specificity, accuracy, repeatability, intermediate precision, and linearity. This assay not only serves as a bioassay for LT activity, but has applications for characterization and quality control of anti-PA therapeutic antibodies or other products that target the AP-1 signaling pathway.

01 Feb 2022·Bundesgesundheitsblatt - Gesundheitsforschung - GesundheitsschutzQ4 · MEDICINE

Behandlung von Hepatitis-C-Infektionen im Zeitalter direkt wirkender antiviraler Medikamente (DAAs)

Q4 · MEDICINE

Review

Author: Zeuzem, Stefan ; Peiffer, Kai-Henrik

02 Nov 2021·Clinical Infectious DiseasesQ1 · MEDICINE

Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures—Same Satisfactory Results, Same Unanswered Questions

Q1 · MEDICINE

Communications

Author: Sulkowski, Mark ; Wyles, David

100 Deals associated with Anthraxumab

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anthrax	Phase 1	Netherlands	IQ Therapeutics BV	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISC2022	Not Applicable	Ischemic stroke	-	Blank-NPA	dvtnoehdsa(nymdibaywk) = nmfezydjxe tllwuxofll (seelbdspzd ) View more	-	01 Feb 2022
				NG-NPA	dvtnoehdsa(nymdibaywk) = zgtbqhvtva tllwuxofll (seelbdspzd ) View more
ASCO_GI2019	Not Applicable	Hepatocellular Carcinoma	-	DAA therapy	(cxfqezjvkl) = wdonaamkeb fvmmyeogot (dxddljmcug, 39.5 - not reached) View more	Positive	29 Jan 2019
				No DAA therapy	(cxfqezjvkl) = jjcqiaxwka fvmmyeogot (dxddljmcug, 9.8 - 14.5)

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data